Literature DB >> 14666662

High ceramide content liposomes with in vivo antitumor activity.

Jennifer A Shabbits1, Lawrence D Mayer.   

Abstract

BACKGROUND: The pro-apoptotic activity of ceramide lipids has made this an exciting new target for therapeutic manipulation. While approaches using exogenous application of short-chain ceramides and modulation of endogenous ceramide levels via manipulation of metabolic pathways have been explored, controlled delivery of natural ceramide has not been previously reported. In this paper we describe the formulation of novel liposomes containing high levels of natural ceramide in the lipid bilayer for the purpose of controlled ceramide delivery.
MATERIALS AND METHODS: Liposomes were characterized by cryo-transmission electron microscopy, quasi-elastic light scattering and trapped volume analysis. Pharmacokinetic analysis was performed following i.v. bolus dosing, and antitumor activity was evaluated following i.v. bolus and i.p. dosing in the J774 ascites tumor model.
RESULTS: Stable ceramide-containing liposomes exhibited pharmacokinetic properties suitable for in vivo applications and resulted in an increase in lifespan of greater than 20% compared to control liposomes following i.v. bolus and i.p. administration.
CONCLUSION: This work demonstrates proof-of-concept that delivery of exogenous natural ceramide lipid has antitumor activity in vivo, and highlights the potential utility of ceramide-based liposomes as a novel strategy for cancer chemotherapy based on controlled ceramide delivery.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14666662

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  6 in total

1.  Targeting of survivin by nanoliposomal ceramide induces complete remission in a rat model of NK-LGL leukemia.

Authors:  Xin Liu; Lindsay Ryland; Jun Yang; Aijun Liao; Cesar Aliaga; Rebecca Watts; Su-Fern Tan; James Kaiser; Sriram S Shanmugavelandy; Andrew Rogers; Kathleen Loughran; Bailey Petersen; Jonathan Yuen; Fanxue Meng; Kendall Thomas Baab; Nancy Ruth Jarbadan; Kathleen Broeg; Ranran Zhang; Jason Liao; Thomas Joseph Sayers; Mark Kester; Thomas P Loughran
Journal:  Blood       Date:  2010-07-29       Impact factor: 22.113

Review 2.  Use of liposomes as drug delivery vehicles for treatment of melanoma.

Authors:  Melissa A Tran; Rebecca J Watts; Gavin P Robertson
Journal:  Pigment Cell Melanoma Res       Date:  2009-05-22       Impact factor: 4.693

3.  PLGA/liposome hybrid nanoparticles for short-chain ceramide delivery.

Authors:  Peng Zou; Stephan T Stern; Duxin Sun
Journal:  Pharm Res       Date:  2013-09-25       Impact factor: 4.200

4.  Calcium phosphate nanocomposite particles for in vitro imaging and encapsulated chemotherapeutic drug delivery to cancer cells.

Authors:  Mark Kester; Yasser Heakal; Todd Fox; Arati Sharma; Gavin P Robertson; Thomas T Morgan; Erhan I Altinoğlu; Amra Tabaković; Mylisa R Parette; Sarah M Rouse; Victor Ruiz-Velasco; James H Adair
Journal:  Nano Lett       Date:  2008-12       Impact factor: 11.189

5.  C2-ceramide induces cell death and protective autophagy in head and neck squamous cell carcinoma cells.

Authors:  Wenyuan Zhu; Xinhua Wang; Yi Zhou; Huiming Wang
Journal:  Int J Mol Sci       Date:  2014-02-21       Impact factor: 5.923

6.  Ceramide-containing liposomes with doxorubicin: time and cell-dependent effect of C6 and C12 ceramide.

Authors:  Anders Øverbye; Ann Mari Holsæter; Fusser Markus; Nataša Škalko-Basnet; Tore-Geir Iversen; Maria Lyngaas Torgersen; Tonje Sønstevold; Olav Engebraaten; Kjersti Flatmark; Gunhild Mari Mælandsmo; Tore Skotland; Kirsten Sandvig
Journal:  Oncotarget       Date:  2017-08-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.